CPHI 2026 Milan — SeamlessBio

SeamlessBio is at CPHI Worldwide 2026 in Milan — Hall 12, F75. If you are dealing with FBS supply pressure, evaluating serum-free alternatives, or looking to qualify a backup supplier for biological raw materials, come talk to us.

Where to Find Us at CPHI 2026

CPHI Worldwide is the largest pharma ingredients show in the world — over 60,000 attendees, 2,500+ exhibitors, and three days of concentrated industry access. If you are in Milan and working in biopharma manufacturing, procurement, or CRO services, find us at Hall 12, Stand F75 to talk about your biological raw material needs.

Schedule a meeting in advance via info@seamlessbio.de.

What Is Keeping Biopharma Procurement Teams Up at Night in 2026

The conversations we are having most often this year — at shows, with CROs, with ATMP manufacturers — come down to three core issues:

1. FBS Supply Is Not Getting Better

The US cattle herd hit a 75-year low at the start of 2026. FBS is a byproduct of beef processing — and when fewer animals go to slaughter, less serum is collected, regardless of what the market needs. Supply constraints will persist through 2028–2029 at minimum. For any organisation that depends on FBS in a validated GMP process, the question is no longer whether to have a contingency plan — it is how good that plan is.

2. Regulatory Pressure on Animal-Derived Materials Is Increasing

EMA, FDA and ICH guidelines are moving in a clear direction: manufacturers of products intended for human use are expected to justify the use of animal-derived materials and to have a defined path toward elimination where technically feasible. For ATMP manufacturers and vaccine producers in particular, this pressure is already shaping procurement decisions today.

3. Serum-Free Media Has Matured — But Transition Takes Planning

Chemically defined, serum-free media for CHO cells, HEK293, Vero, MDCK and T-cell expansion now perform comparably to serum-supplemented alternatives at commercial scale. The barrier is not biology — it is process development investment and change management. For organisations planning new manufacturing campaigns or facility expansions, now is the right time to evaluate the transition.

What SeamlessBio Brings to the Table

SeamlessBio connects CROs, ATMP manufacturers, vaccine producers and research institutions in EU and UK with verified biological raw materials and supply chain solutions. Our portfolio covers:

• FBS and bovine sera — multiple geographic origins, full traceability documentation, GMP-aligned
• Menschliches Serum — Standard, Type AB, Male, OTC, Delipidated, Heat-Inactivated and more; xeno-free for ATMP and clinical applications
• BSA and HSA — for cell culture, diagnostic and pharmaceutical applications
• Single-Use Bioprocess Bags and Tankliner — for scale-up and manufacturing operations
• Cell4Pharma DMPK Assay Kits — for early drug metabolism and pharmacokinetics screening at CROs

We are not a catalogue supplier. We source, verify and qualify — and we connect the right partners to the right buyers, with the documentation your procurement process requires.

Serum-Free Media in Vaccine and ATMP Manufacturing

For vaccine production in Vero, MDCK, HEK293 and CHO cells — and for ATMP manufacturing using T cells, MSCs and iPSC-derived products — serum-free and chemically defined media are increasingly the expected standard, not an upgrade. The regulatory case is clear: fewer adventitious agent risks, cleaner validation dossiers, and better batch-to-batch consistency.

Häufig gestellte Fragen